Friday, July 4, 2025 7/4/2025

Adenoviral delivery of protein-based therapeutics to the tumor microenvironment

Award Number: F32CA189372
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/01/2015
PERIOD OF PERFORMANCE END DATE: 03/31/2018

Group Awards By:

View Award Description

Adenoviral delivery of protein-based therapeutics to the tumor microenvironment - ¿ DESCRIPTION (provided by applicant): Abstract A major limitation of current strategies targeting growth factors in cancer is achieving a high local concentration of therapeutics to keep growth factors at very low levels for extended periods of time. In vivo production of monoclonal antibody (mAb)-based therapeutics in tumor cells provides an attractive alternative to treatment with repeated high bolus injections, as expression of the secreted therapeutic in tumor cells could provide high local concentrations that could act in a paracrine fashion to quench growth factors in the tumor microenvironment with minimal side effects. In contrast to "tumorlytic" viral approaches, this strategy does not require that all tumor cells be infected, as uninfected cells are still subject to bystander effects of the secreted therapeutic. My project focuses on the use of an adenoviral delivery system to transduce tumor cells with genes encoding secreted payloads for the paracrine delivery of protein-based therapeutics to the tumor microenvironment. These payloads consist of growth factor neutralizing agents that target a series of growth factors overexpressed in cancer (i.e. IL-6, HGF, IGF-1, and EGFR-family associated ligands). My project accomplishes this objective through two specific aims. Aim 1: To develop an adenoviral delivery system for tumor production of payloads in HER-2 expressing tumor lines. Using an adaptor system that utilizes a specific target module for the delivery of an adenovirus to HER2-overexpressing tumors, I will test a series of growth factor neutralizing agents for delivery and secretion efficiency in HER2 tumor cell lines. Aim 2: To evaluate efficacy and safety of adenoviral treatment in HER2-expressing tumors in a murine model. Using SCID mice harboring HER2-positive tumors, the delivery system described will be use to transduce tumor cells with genes encoding these therapeutic agents.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $8,850 )
2017	2017	UNIVERSITAT ZURICH	RAMISTRASSE 71	ZURICH	ZH	8006		CHE	Cancer Research Manpower	001	3	2/28/2017	NON-COMPETING CONTINUATION	$8,850
														Subtotal = $8,850

Issue Date FY: 2016 ( Subtotal = $8,850 )
2016	2016	UNIVERSITY OF ZURICH	WINTERTHURESTRASSE 190	ZURICH				CHE	Cancer Research Manpower	001	2	3/23/2016	NON-COMPETING CONTINUATION	$8,850
														Subtotal = $8,850

Issue Date FY: 2015 ( Subtotal = $7,850 )
2015	2015	UNIVERSITY OF ZURICH	WINTERTHURESTRASSE 190	ZURICH				CHE	Cancer Research Manpower	002	1	7/23/2015	NEW	$7,850
														Subtotal = $7,850

Grand Total All Awards = $25,550

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Adenoviral delivery of protein-based therapeutics to the tumor microenvironment

Award Number: F32CA189372

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/01/2015

PERIOD OF PERFORMANCE END DATE: 03/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer